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Abstract 
Cytosolic NADP’-dependent malic enzyme (ME) from human tumor cells was characterized in detail and compared to ME from normal human 
tissues produced in recombinant E. coli. Kinetic properties, size as seen in SDS gels, and HPLC elution profiles of tryptic digests of human ‘normal 
cell’ ME and NADP’-ME from tumor cells were identical. Thus, NADP’-ME found in tumor cells does not constitute a tumor-specific isoform as 
suggested by other studies but is identical to the ‘housekeeping protein’ predominantly expressed in human liver and white adipose tissue. 
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1. Introduction 
Three different isoforms of malic enzyme (ME) are 
found in mammalian tissues: mitochondrial NAD’-ME 
(EC 1.1.1.39), mitochondrial NADP’-ME (EC 1.1.1.40), 
and cytosolic NADP’-ME (EC 1.1.1.40). Mitochondrial 
NAD’-ME is found in rapidly proliferating tissues, par- 
ticularly tumor cells [1,2]. Mitochondrial NADP’-ME is 
found in tissues with low division rates such as heart, 
muscle and brain [3]. Cytosolic NADP’-ME is expressed 
in liver and adipose tissue [3] and generates NADPH 
needed for fatty acid biosynthesis. It is under dietary 
control and can be induced by a carbohydrate-rich diet 
or thyroid hormones [3,4]. An earlier study [5] suggested 
that absence or deficiency of NADP’-ME is a marker for 
malignancy, at least in lymphoid cells. However, signifi- 
cant activities of a cytosolic NADP’-ME with immuno- 
logical cross-reactivity to cytosolic NADP’-ME from pi- 
geon liver have recently been described in a human 
breast carcinoma cell line [6,7]. These papers also re- 
ported differences in the pI and in the electrophoretic 
mobility of cytosolic ME from tumor and normal tissues, 
suggesting the presence of a tumor-specific isoform. We 
have found cytosolic NADP’-ME in several human tu- 
mors cell lines. To determine whether this NADP’-ME 
differs from the ME in normal tissue, we have cloned this 
isoform from a human fat cell cDNA library and ex- 
pressed it in E. coli. The nucleotide sequence of the 
human ME cDNA and its derived amino acid sequence 
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is similar to the NADP’-ME from mouse and rat liver 
[8,9]. The recombinant protein had identical kinetic 
properties when compared to cytosolic NADP’-MEs 
isolated from human liver and different tumor cells. Re- 
verse-phase HPLC of tryptic digests of purified NADP+- 
ME from human tumor cells and recombinant human 
ME shows the same elution pattern of the tryptic frag- 
ments. This demonstrates that there is no difference be- 
tween the isoform of cytosolic NADP+-ME expressed in 
normal and in tumor tissues. 
2. Materials and methods 
2.1. ME analysis in cell and tissue lysates 
A 549 cells (ATCC: CCLl85), Co10 205 cells (CCL 222), MCF 7 cells 
(HTB 22) and RPM1 1788 cells (CCL 156) were grown in DMEM+ 10% 
FBS. 2 x 10’ cells were washed and collected by centrifugation at 
500 x g. The pellet was resuspended in 5 ml lysis buffer (50 mM Tris- 
HCl, pH 7.4, 3 mM MgCl,, 20 mM KCl, 0.4 mM DTT, 0.5 mM PMSF, 
0.05% NP40, 25% glycerol), sonicated and clarified by spinning at 
20,000 x g. Human heart mitochondria were prepared as described in 
[lo]. 5 rng protein were loaded on a Pharn&ia 5/5 MonoQ FPLC 
column and eluted with a 20-180 mM KC1 gradient. ME activity was 
assayed as described in [l 11. K, assays were p&formed fluoromethcally 
at 40 different malate concentrations between 0 and 0.5 mM. 
2.2. Pur$cation of human cytosolic ME from Co10 205 cells 
5 x 10’ cells were lysed in 50 ml lysis buffer and purified using ion- 
exchange chromatography (TMAE fractogel; Merck 16881), NADP+- 
affinity-chromatography IPharmacia 27-5444) and gel-filtration (Su- 
nerose 6: Pharmacia) in 25 mM Tris-HCl. DH 7.4. 3 mM M&l,. 0.5 
1 _I - _/ 
mM EDTA. This procedure yielded a homogeneously pure protein as 
seen in SDS-polyacrylamide gels. 
2.3. Cloning, sequencing and expression of human cytosolic ME 
A human fat cell cDNA library (Clontech 1108b) was screened with 
a cDNA clone of duck ME [12] using radioactive plaque hybridization 
at reduced stringency [13]. Inserts of positive phages were re-cloned into 
Bluescript KS(+) using standard procedures [13]. The DNA sequence 
was determined from the double-stranded plasmid on a ABI373A se- 
quencer with 25 custom made ME-specific primers and fluorescence- 
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labelled dideoxynucleotides overlapping and for both strands. To ex- 
press the open reading frame of human cytosolic ME in bacteria, an 
XhoI site was fused to the ATG start codon and a HindlII site to the 
stop codon using PCR amplification. This expression cassette was 
cloned into the expression vector pRH281 as described previously for 
NAD÷-ME [11]. Recombinant protein was purified as described for 
ME from Colo 205 cells (above). 
2.4. Tryptic digest and HPLC characterization f ME. 
40pg ME from Colo 205 cells or ME from recombinant E. coli were 
digested overnight in 10 pg/ml trypsin (Boehringer-Mannheim; se-
quencing rade). The resulting peptides were separated with reverse- 
phase HPLC using a Merck Supersphere column (125-4, 100A, 4pM).  
Peptides were eluted with 70 ml of a linear gradient of 0.1% tri- 
fluoroacetic acid in water (A) and acetonitrile (B). The elution profile 
was monitored at 214 nm.The tryptic peptides were collected, dried and 
analyzed on a ABI 477A pulsed liquid-phase sequencer. 
3. Results 
E3 
0 
'<1 
3.1. Characterization f the chromatographic behavior of 
malic enzyme isoforms 
We have found that FPLC ion-exchange chromatog- 
raphy on a MonoQ column allows rapid and reproduci- 
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zyme (ME). Assays from a crude lysate cannot distin- 
guish between cytosolic and mitochondrial NADP+-ME; 
other enzymatic activities, such as lactate dehydrogenase 
(LDH), interfere with the assay for NAD+-ME. Fig. 1 
shows elution profiles of the NAD +- and NADP+-ME of 
a human heart lysate, which expresses all three isoforms 
of ME [3,14]. After loading, the Mono Q columns were 
eluted with a 20-180 mM KCI gradient. NADP+-ME 
activity eluted at KC1 concentrations of 50 and 130 mM, 
and NAD+-ME eluted at 110 mM KC1. Enzymes inter- 
fering with the NAD÷-ME assay (LDH isoforms) elute 
at 30, 80, 90 mM KC1, respectively (data not shown). No 
ME activity (NADP ÷ or NAD+-linked) was in the 
flowthrough or a 1 M KC1 wash of the column of all 
lysates tested. To characterize the subcellular locations 
of the ME activities, mitochondria were prepared from 
human heart muscle and the mitochondrial extract was 
separated under the same conditions. Fig. 1 shows the 
presence of NADP+-ME at 50 mM KC1 and NAD+-ME 
at 110 mM KC1. No NADP+-ME eluted at 130 mM KC1. 
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Fig. 1. FPLC elution profiles of NAD ÷- and NADP÷-ME activities from a total lysate of human heart, isolated human heart mitochondria, Colo 
205 and RPMI1788 cells, as indicated. After loading on a MonoQ column, samples were eluted with a 40 ml 213~180 mM KCI gradient with a flow 
rate of 0.5 ml/min. 
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Therefore, the enzyme luting at 130 mM KC1 was iden- 
tified as cytosolic NADP÷-ME, the enzyme luting at 50 
mM KC1 as mitochondrial NADP+-ME, and the enzyme 
eluting at 110 mM KC1 as mitochondrial NAD÷-ME. 
3.2. Two isoforms of  ME are present in tumor cell lines 
Colo 205, A 549 and RPMI1788 cell extracts were 
separated on MonoQ columns (Fig. 1, Table 1). In all 
tumor cell lines, activities of NAD+-ME were found at 
110 mM KC1 and activities of NADP+-ME were found 
at 130 mM KC1. No NADP+-ME activity eluted at 50 
mM KC1. To verify the absence of mitochondrial 
NADP÷-ME, a separation into cytosolic and mitochon- 
drial fractions was performed and the relative distribu- 
tion of the respective activities was measured. In Colo 
205, A 549 and RPMI1788 cells all NAD+-ME activity 
was in the mitochondrial fraction. As expected from the 
FPLC separations, all tumor cells lacked mitochondrial 
NADP+-ME activity, whereas significant NADP+-ME 
activity was present in the cytosolic fraction. Table 1 
gives the specific activities (mU ME/mg protein) in 
tumor cell extracts; they contain considerable amounts 
of NAD ÷- as well as NADP+-ME, with the colon carci- 
noma and the lymphoid cell line containing about twice 
as much NAD+-ME as NADP+-ME. 
3.3. Isolation of a eDNA of  eytosolic NADP÷-ME from 
human fat cells and expression in E. coli 
To characterize the properties of the cytosolic ME 
found in liver and adipose tissue and to compare its 
properties to those of NADP÷-ME from tumor cells, we 
have isolated and sequenced its cDNA from a human fat 
cell cDNA library. Our approach to cloning was a pla- 
que hybridization under reduced stringency using a duck 
liver ME cDNA [12] as a probe. Of a total of 10 6 phage 
plaques, 20 were positive after plaque purification. One 
of them coded for a full-length clone of 2,058 bp ending 
just 1 bp ahead of the ATG start codon. The sequence 
for the cDNA and the deduced amino acid sequence is
shown in Fig. 2. It has an open reading frame of 1,719 
bp coding for a protein of 572 amino acids with a molec- 
ular weight of 64.1 kDa. The 3' untranslated region is 
339 bp long; a consensus ignal for polyadenylation 
(AAATAA) is located 10 bp upstream of the poly(A)- 
Table 1 
Activities of NAD ÷- and NADP+-dependent malic enzymes in human 
tumor cells 
Source NADP÷-ME NAD+-ME 
Colo 205 6.2 _+ 0.6 10.9 _+ 1.7 
A 549 8.0 + 2.3 6.5 _+ 1.9 
RPM! 1788 9.3 +_ 2.5 20.7 + 6.3 
hu. heart 4.8 _+ 0.9 4.1 -+ 0.2 
Activities of mitochondrial NAD ÷- and cytosolic NADP+-ME in tumor 
cells and normal heart issue are given in mU/mg of total protein in the 
extract based on three independently prepared lysates. 
tail. The encoded protein is similar to cytosolic NADP +- 
ME cloned from mouse [8] or rat liver [9], showing an 
identity of 89%. Most of the amino acid changes are 
conservative exchanges. The cytosolic duck ME [12] is 
more distantly related to the human isoform; the identity 
is 77%. Most of the differences between the duck and the 
human and rat ME are clustered in the N- and C-termi- 
nal regions of the protein, with the central portion show- 
ing the highest degree of conservation. Compared to 
human mitochondrial NAD+-ME [11], significant differ- 
ences are found. There is only 54% identity between the 
two human MEs which is close to the 50% homology to 
NADP÷-ME from maize chloroplasts [15]. In both cases, 
the differences are scattered throughout the protein. 
To express the coding region of human cytosolic 
NADP+-ME in E. coli, a bacterial ribosome binding site 
was fused to the 5" end using PCR amplification. This 
construct was cloned into the expression vector 
pRH281T [11] and transfected into E. coli. Induction with 
indoleacrylic acid resulted in high level expression of the 
recombinant ME. After purification, 1mg of fully active 
human NADP÷-ME was obtained per liter bacterial broth. 
3.4. Cytosolic tumor cell ME  is identical to the 'normal' 
liver and fat  cell ME  
In order to ascertain whether tumor cells express a 
cytosolic ME which differs from that in normal cells, we 
compared the recombinant human NADP+-ME to the 
cytosolic ME from tumor cells. NADP+-ME from Colo 
205 cells was purified to near homogeneity. After purifi- 
cation, the protein showed a single band corresponding 
to a size of 62 kDa in a silver-stained SDS-poly- 
acrylamide gel (Fig. 3). Recombinant human NADP ÷- 
ME was purified to homogeneity from E. coli using es- 
sentially the same procedure as for Colo 205 cells. The 
purified human recombinant protein had the same mo- 
bility in an SDS-polyacrylamide g l as the protein from 
human tumor cells (Fig. 3). The specific activity for both 
proteins is 40 mU/gtg protein; this is close to the specific 
activity of 56 mUStg protein reported for cytosolic 
NADP÷-ME from human liver [16], but significantly 
higher than the specific activity of 5 mU/#g reported for 
cytosolic NADP+-ME from a human breast cancer cell 
line [6]. Since ME is rather unstable in dilute form, differ- 
ences in the purification protocol may account for these 
discrepancies. The pH optimum of the recombinant and 
the colon carcinoma cell ME is about 7.2, and both 
proteins exhibit about 50% of their optimal activity at 
pH 6.6. The K m for malate is 316 ,uM for colon carci- 
noma ME, which is comparable to the Km of 271/IM for 
recombinant human 'normal cell' ME. 
To compare these values with the cytosolic MEs from 
other tumor cells, we partially purified cytosolic 
NADP+-ME from MCF 7, A 549, RPMI 1788 cells and 
from normal human liver and assayed their Km for 
malate (Table 2). The Km was in the same range 
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i ATGGAGCCCq~GCCCCCCGTCGCCGCCACACCCATCAGCGCGGCTACCTGCTGACACGGAACCC~CACCTCAAC~GGACTTGGCCTTT 
[M E P E A P R R R l H T H Q R G Y L L Y R N P H L N K D L A F 
A13 
91 ACCCTGG~GAGAGACAGC~TTG~CATTCATGGATTGTTGCCACCTTCCTTCAACAGTCAGGAGATCCACGTTCTTAGAGTAGTA~ 
T L E E R Q Q L N I H G L L P P S F N S Q E I Q V L R V V K  
181 ~TTTCGAGCATCTG~CTCTGA~TTTGACAGGTATCTTCTCTT~TGGATCTCC~GATAGAAATG~AAACTCTTTTATAGAGTGCTC 
N F E H L N S D F D R Y L L L M D L Q D R N E K L F Y R V L  
271 ACATCTGACATTGAGAAATTCATGCCTATTGTTTATACTCCCACTGTGGGTCTGGCTTGCC~C~TATAGTTTGGTGTTTCGGAAGCCA 
T S D I E K F M P I V Y T P T V G L A C Q Q Y S L V F R K P  
361 AGAGGTCTCTTTATTACTATCCACGATCGAGGGCATATTGCTTCAGTTCTC~TGCATGGCCAG~GATGTCATC~GGCCATTGTGGTG 
R G L F I T I H D R G H I A S V L N A W P E D V ~ K A I V V  
451 ACTGATGGAGAGCGTATTCTTGGCTTGGGAGACCTTGGCTGT~TGG~TGGGCATCCCTGTGGGTAAATTGGCT~TATATACAGCTTGC 
T D G E R I L G L G D L G C N G M G I P V G K L A L Y T A C  
541 GGAGGGATG~TCCTC~G~TGTCTGCCTGTCATTCTGGATGTGGG~CCGAAAATGAGGAGTTACTTAAAGATCCACTCTACATTGGA 
G G M N P Q E C L P V I L D V G T £ N E E L L K D P L Y I G  
631 C~ACGGCAGAG~GAGT~GAGGTTCTG~TATGATGATTTTTTGGACG~TTCATGGAGGCAGTTTCTT~C~GTATGGCATG~TTGC 
L R Q R R V R G S E Y D D F L D E F M E A V S S K Y G M N C  
721 CTTATTCAGTTTG~GATTTTGCC~TGTG~TGCATTTCGTCTCCTG~C~GTATCG~ACCAGTATTGCACATTC~TGATGATATT`  
L I Q F E D F A N V N A F R L L N K Y R [ N Q Y C T F N D D I ~  
A50 
811. C~GG~CAGCATCTGTTGCAGTTGCAGGTCTCCTTGCAGCTCTTCG~T~CC~G~CAAACTGTCTGATCAAAC~TACTATTC~ ~ Q G T A S V A V A G L L A A L K I I T K N K L S O Q T I L F Q  
901 GGAGCTGGAGAGGCTG~TAGGGATTGCACA~TGATTGTGATGG~TTGGAAAAAG~GGTTTA~CAAAAGAGAAAGC~ATCAAAAAG 
G A G E A A L G I A H L I V M A L E K E G L P K E K A I K K  
991 ATATGG~TGGTTGATTCA~GGATT~TAGTT~GGGACGTGCTTCCTT~CAC~GAGAAAGAG~GTTTGCCCATG~ATG~G~ 
I W L V D S K G L I V K G R A S L T Q E K E K F A H E H E £  
1081 ATG~G~CCTAG~GCCATTGTTC~GAAATAAAACC~CTGCCCTCATAGGAGTTGCTGC~TTGGTGGTGCATTCTCAG~CAAATT 
M K [ N L E A I V Q E I K P T A ' L ' I I G V A A I G G A F S E Q I  
855 
1171 CTCAAAGATATGGCTGCCTTC~TG~CGGCCTATTATTTTTGCTTTGAGT~TCC~CTAGCAAAGCAG~TGTTCTGCAGAGCAGTGC 
L K D M A A F N E R P I I F A L S N P T S K A E C S A E Q C  
1261 TACAAAAT~CC~GGGACGTGC~TTTTTGCCAGTGGCAGTCCTTTTGATCCAGTCACTCTTCCAAATGGACAGACCCTATATCCTGGC 
Y K I T K G R A I F A S G S P F D P V T L P N G Q T L Y P G  
1351 C~GGC~C~TTCCTACGTGTTCCCTGGAGTTGCTCTTGGTGTTGTGGCGTGTGGATTGAGGCAGATCACAGAT~TATTTTCCTCACT 
Q G N N S Y V F P G V A L G V V A C G L R Q I T D N I F L T  
1441 ACTGCTGAGGTTATAGCTCAGC~GTGTCAGATAAACACTTGG~GAGGGTCGGCTTTATCCTCCTTTG~TACCATTAGAGATGTTTCT 
T A E V I A Q Q V S D K H L E £ G R L Y P P L N T I R D V S  
1531 CTGAAAATTGCAGAAAAGATTGTGA~GATGCATACC~GAA/~GACAGCCACAGTTTATCCTG~CCGCAAAAC~AG~GCATTTGTC 
L K I A E K I V K D A Y Q E K T A T V Y P E P Q N K E A F V  
1621 CGCTCCCAGATGTATAGTACTGATTATGACCAGATTCTACCTGATTGTTATTCTTGGCCTG~GAGGTGCA~A~ATACAGACCA~GTT 
R S Q M Y S T D Y D Q I L P D C Y S W P E E V Q K I Q T K V  
1711 GACCAG~d~GAT~TAGCAAACATTTCT~CTCTATT~TGAGGTCTTTAAACCTTTCATAATTTTTA~GGTTG~TCTTTTAT~%TG 
D Q STOP 
1801 ATTCATAAGACACTTAGATTAAGATTTTACTTT~CAGTCT~AAATTGATAG~G~TATCGATATAAATTGGGAT~ACATCACATGA 
1891 GAC~TTTTGCTTCACTTTGCCTTCTGGTTATTTATGGTTTCTGTCTG~TTATTCTGCCTACGTTCTCTTTA~AGCTGTTGTACGTAC 
1981 TACGGAGAAACTCATCATTTTTATACAGGACACT~TGGG~GACCAAAATTACT~TAAATTGA~TAACCAACATT 2058 
Fig. 2. cDNA and deduced amino acid sequence of the human cytosolic NADP+ME. The deduced amino acid sequence is shown below the 
corresponding nucleotide sequen~ in the single letter code. Amino acids in boxes correspond to peptide sequences of t~ptic peptides of ME ~und 
to be di~rent when cornering HPLC elution patterns of human NADP+-ME ~om Colo ~5 cells and recombinant E co~. The DNA sequence 
has been submitted to the Genban~EMBL Data Bank with the accession umber X772~. 
(300 + 50/~M) for all the enzymes derived from the dif- 
ferent tumor cell lines and normal tissues, suggesting that 
the same isoform is expressed. It is also close to the Km 
of  216 + 155/IM for malate reported for the ME isolated 
from a human breast cancer cell line [6]. As a final step 
towards the characterization of  the cytosolic 'tumor cell' 
ME we made a tryptic digest of  the pure ME from Colo 
205 cells and of the recombinant 'normal cell' ME. The 
digests were loaded onto a reverse-phase HPLC column 
and eluted under identical conditions. The elution pro- 
files (OD214 nra) are essentially identical; only three signif- 
icant differences were found (labelled with arrows in Fig. 
4). To characterize these differences, we have analyzed 
the amino acid sequences of  the corresponding oligopep- 
tides. Peaks 13 and 50 from the human recombinant ME 
and peak 55 from the Colo 205 ME were the result of  
incomplete tryptic digestion, since they contained internal 
lysines or arginines. The sequences of  the oligopeptides 
of  all three peaks were present in the amino acid sequence 
of the normal cell NADP+-ME (boxed in Fig. 2). 
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Fig. 3. SDS-polyacrylamtde gel electrophoresis of recombinant human 
cytosolic NADP’-ME produced in E. coli (lane 1) and cytosolic 
NADP’-ME from a human colon carcinoma cells (Co10 205; lane 2). 
M, molecular weight markers. After separation, the gel was stained 
using a Bio-Rad silver staining kit. 
These data show that cytosolic ME expressed in Co10 
205 cells is identical to the NADP’-ME expressed in 
normal liver and fat cells. Further, it is unlikely that there 
are any significant posttranslational modifications of the 
protein in human tumor cells, since the elution pattern 
of the tryptic digest from reverse phase HPLC should 
have revealed even minor differences. 
4. Discussion 
In this study, we have characterized cytosolic NADP+- 
ME from different human tumor cell lines and compared 
it to recombinant human cytosolic NADP+-ME ex- 
pressed in normal tissue. Taken together, the findings 
are: 
(a) There is a substantial amount of cytosolic NADP’- 
ME in a variety of human tumor cell lines derived from 
different organs, including colon, breast and lung and in 
a lymphoid cell line. An earlier study [5] suggested that 
deficiency of cytosolic ME is a possible marker for ma- 
lignancy in lymphoid cells. This conclusion cannot be 
extended to tumor cells derived from tissues of epithelial 
origin, since all carcinoma cell lines used in this study 
have considerable NADP+-ME activities. The lymphoid 
cell line (RPM11788) used in this report also has signifi- 
cant activities of cytosolic NADP’-ME. However, this 
finding does not necessarily contradict the report of 
Povey et al. [5] since RPM11788 cells are not derived 
from a malignant leukaemia, but were established from 
peripheral lymphocytes of a healthy donor. An extended 
study investigating the status of the different ME 
isoforms in a large number of human cell lines is cur- 
rently being done. 
(b) We did not find any mitochondrial NADP+-ME in 
the tumor cell lines tested. This finding differs from a 
report of an increase in mitochondrial NADP’-ME of 
preneoplastic and tumor-derived rat tracheal cells when 
compared to corresponding normal primary cells [17]. 
However, it is possible that this reported increase in 
NADP’-ME activity reflected mitochondrial NAD’-ME 
since, in contrast to the human NAD’-ME which is 
hardly active with NADP’ [l 11, rat NAD’-ME has sig- 
nificant activity when assayed with NADP’ [l]. 
(c) The cytosolic NADP’-ME expressed in the tumor 
cells used in this study is the same as the ME expressed 
in normal liver and adipose tissue. Post-translational 
modifications specific for tumor cells affecting the activ- 
ity of the protein are unlikely since the recombinant ME 
has the same size, as seen in SDS-polyacrylamide gels 
(Fig. 3) the same K, for malate (Table 2) and the same 
specific activity (40 mU/pg). Furthermore, reverse-phase 
HPLC elution is very sensitive and could be expected to 
have picked up even minor differences if any existed. The 
differences between cytosolic tumor cell ME and pigeon 
liver ME described by Chang et al. [6] are most likely due 
to species-specific differences between the pigeon and the 
human enzyme; duck liver ME, which is probably very 
similar to pigeon liver ME, is only 77% identical to 
human liver ME, and large stretches at the N- and the 
C-termini of the protein show significant differences. 
What is the significance of the expression of cytosolic 
ME in tumor cells? In normal tissues, this enzyme pro- 
vides NADPH for fatty acid biosynthesis. However, in 
a study in progress we found that the NADPH produc- 
tion by ME was small when compared to glucose-6- 
phosphate dehydrogenase or NADP’-dependent iso- 
citrate dehydrogenase the activity of which is about 50% 
cytosolic. It is unlikely that cytosolic ME contributes 
significantly to the NADPH pool in the cytoplasm of the 
tumor cells. It is more likely that pyruvate is the relevant 
product of the ME reaction in tumor cells. The signifi- 
cance of mitochondrial NAD’-ME is thought to be re- 
lated to the use of glutamine as a respiratory fuel, in a 
pathway from glutamine to lactate that has been named 
glutaminolysis [18]. This pathway not only provides en- 
ergy by using a truncated Krebs cycle from a-ketogluta- 
rate to malate, it also produces intermediates for ana- 
Table 2 
K,,, values of human cytosolic NADP’-ME from different tumor cells 
and normal tissues 
A549” 313 f 22/~M 
Colo205” 316+58/~M 
MCF 7” 357 f 82 PM 
RPM1 1788” 338 f 93 /LM 
recomb. humanb 271 + 60pM 
human liver” 331 f 73 ,uM 
K,,, assays were performed with 3 different and independent prepara- 
tions of malic enzyme; data were plotted in a Hanes-Woolf plot. Stand- 
ard deviations are included. “Partially purified protein after fractiona- 
tion on a MonoQ ion-exchange column. ‘Pure protein. 
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Fig. 4. Reverse-phase HPLC chromatography of tryptic fragments of recombinant human cytosolic NADP’-ME (track A) and cytosolic NADP’-ME 
from human Co10 205 cells (track B). Significant differences in the elution profile are indicated by arrows. Peptides corresponding to these peaks 
were collected for sequence analysis. 
bolic purposes in tumor cells, e.g. aspartate and nitrogen 
groups for DNA biosynthesis. Malate generated from 
glutamine in the mitochondria has three possible op- 
tions: conversion to oxaloacetate by malate dehydroge- 
nase, decarboxylation to pyruvate in the mitochondria 
by NAD’-ME, or transport into the cytoplasm. Here, 
malate can be decarboxylated by cytosolic ME with sub- 
sequent conversion to lactate by lactate dehydrogenase. 
NAD+ produced by this reaction can be used by glycer- 
aldehyde-3-phosphate dehydrogenase, thus compensat- 
ing for the expression of a partially inactive pyruvate 
kinase in tumor cells [21]. A significant proportion of 
glutamine taken up by tumor cells and lymphocytes ends 
up in lactate, which is secreted [18-201. Therefore, a pos- 
sible function of the cytosolic NADP’-ME in tumor cells 
is the conversion of excess mitochondrial malate, which 
can cross the mitochondrial membrane readily, to py- 
ruvate, which is subsequently converted to lactate and 
extruded from the tumor cell. 
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